Response to Biologics Along a Gradient of T2 Involvement in Patients With Severe Asthma: A Data-Driven Biomarker Clustering Approach

Eileen Wang(National Jewish Health), Bassam Mahboub(Dubai Health Authority), Guy Brusselle(Ghent University Hospital), Riyad Al‐Lehebi(Alfaisal University), Mariko Siyue Koh(SingHealth), Liam G. Heaney(Queen's University Belfast), Dóra Lúðvíksdóttir(Reykjavík University), Njira Lugogo(University of Michigan), Sinthia Bosnic‐Anticevich(University of Sydney), James Fingleton(Capital and Coast District Health Board), Trung N. Tran(AstraZeneca (Japan)), Flavia Hoyte(National Jewish Health), Giorgio Walter Canonica(Ospedale Policlinico San Martino), Richard W. Costello(Beaumont Hospital), John Busby(Queen's University Belfast), Michael E. Wechsler(National Jewish Health), Kenneth R. Chapman, George Christoff(Tokuda Hospital), Désirée Larenas‐Linnemann(Hospital Médica Sur), Mina Gaga, Peter G. Gibson(Hunter Medical Research Institute), Nicholas Chapman(National Jewish Health), Alan Altraja(University of Helsinki), William Henley(Observational & Pragmatic Research Institute), Sverre Lehmann(University of Bergen), А. S. Belevskiy(Pirogov Russian National Research Medical University), Leif Bjermer(Lund University), Susanne Hansen(University of Ioannina), Céline Bergeron(University of British Columbia), Shawn D. Aaron(Ottawa Hospital), Richard Hubbard(National Institute for Health and Care Research), Κonstantinos Κostikas(University of Ioannina), Victoria Carter, Borja G. Cosío(Hospital Universitario Son Espases), Unnur Steina Björnsdóttir(National University Hospital of Iceland), Mona Al‐Ahmad(Kuwait University), Rohit Katial(National Jewish Health), Enrico Heffler(Humanitas University), Takashi Iwanaga(Kindai University Hospital), João Fonseca(Universidade do Porto), Lauri Lehtimäki(Tampere University Hospital), Mark Hew(Monash Health), Aaron Beastall(Observational & Pragmatic Research Institute), David J. Jackson(King's College London), Arnaud Bourdin(Centre National de la Recherche Scientifique), Takahiko Horiguchi(Toyota Motor Corporation (Switzerland)), Peter Barker(Leiden University Medical Center), Lakmini Bulathsinhala, Renaud Louis(University of Liège), Piotr Kuna(Medical University of Lodz)
The Journal of Allergy and Clinical Immunology In Practice
September 2, 2025
10.1016/j.jaip.2025.08.021
Cited by 1

Related Papers

The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
|Allergy|2018|1.4k
The <scp>EAACI</scp>/<scp>GA</scp><sup>2</sup><scp>LEN</scp>/<scp>EDF</scp>/<scp>WAO</scp> Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update
|Allergy|2014|1.2k
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
|Allergy|2021|1.2k
Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
|Allergy|2004|1.1k
Inflammatory subtypes in asthma: Assessment and identification using induced sputum
|Respirology|2006|939